Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Cibinqo impending approval to shake up EU atopic dermatitis market with heightened competition, says GlobalData

Pfizer’s Cibinqo (abrocitinib) is likely to be approved by the EU for the treatment of ‘moderate to severe’ atopic dermatitis (AD) by this year-end ensuing a positive European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) opinion on 15 October 2021. Following the approval of Lilly/Incyte’s Olumiant (baricitinib), and more recently AbbVie’s […]
Read more

Growth potential for India in innovation and R&D, says GlobalData

India has the third largest pharma market in the world by volume, according to research by GlobalData, placing it behind giants such as the US and China. The leading data and analytics company notes that India’s potent manufacturing capabilities, high export activity and large generics market have supported the country in grabbing ‘bronze place’. According […]
Read more

Addition of SGLT2 inhibitor with improved efficacy will be able to address demands of T2D market, says GlobalData

At the 57th annual European Association for the Study of Diabetes (EASD) 2021 meeting, results were presented for a 3-year prospective study. The study results demonstrated that sodium glucose cotransporter 2 inhibitor (SGLT2I), either empagliflozin (Jardiance) or dapagliflozin (Farxiga), are efficacious as part of a quadruple combination therapy with metformin, dipeptidyl peptidase-4 inhibitor (DPP-4I) and […]
Read more

Improving diversity in clinical trials ensures public health strategies are appropriately tailored to all populations, says GlobalData

Data presented at the 14th AACR* Conference in early October revealing that black patients were significantly more likely to be excluded from pancreatic clinical trials than white counterparts is unfortunately not the only instance of this occurring, says GlobalData. The leading data and analytics company notes that there is an ever-growing concern of ethnic disparity […]
Read more

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty sees over 200% rise in sales forecasts for Q3 vs Q2, says GlobalData

The sales forecast for Pfizer/BioNTech’s COVID-19 vaccine Comirnaty has been upwardly adjusted by GlobalData due to anticipated demand for booster shots. The leading data and analytics company has increased its forecasts for Comirnaty’s sales by a phenomenal 190% and 228% in 2022 and 2023, respectively. The drug is now expected to see sales totalling $28.4bn […]
Read more

Opportunities remain for drug developers to address unmet needs in axillary hyperhidrosis therapeutics market, says GlobalData

The lack of available treatments for axillary hyperhidrosis (AH), a disease characterized by increased sweat production in the armpits, offers an opportunity for pharmaceutical and biotechnology companies, according to GlobalData, a leading data and analytics company. Mandana Emamzadeh, PhD, Pharma Analyst at GlobalData, comments: “GlobalData has identified several key unmet needs in the AH space, […]
Read more

Major depressive disorder market to reach $7.87bn in 8MM by 2029, with eight new pipeline products set to capture 62.9% of sales, says GlobalData

The prevalence of major depressive disorder (MDD) symptoms are expected to increase due to COVID-19-related stress, as patients struggled with a loss of personal freedom, conflicting messages from authorities and concerns with health security Increased activity is expected in digital therapeutics (DTx) as pharmaceutical companies aim to fill the unmet need of improved patient education […]
Read more

COVID-19 brings mixed fortunes for commercial dose CMOs, says GlobalData

The contract manufacturing industry for finished dose pharmaceuticals had the lowest growth rate in a decade in 2020, according to GlobalData estimates. The leading data and analytics company reveals that total commercial dose contract manufacturing organization (CMO) contract revenue in 2020 grew by only 2.4% over 2019 revenue. Adam Bradbury, Pharma Analyst at GlobalData, comments: […]
Read more

Valneva’s COVID-19 vaccine will be strong competition for AstraZeneca and J&J, says GlobalData

Following the news that Valneva’s COVID-19 vaccine showed superior neutralizing antibody levels and an equal seroconversion rate and protection against SARS-CoV-2, compared to AstraZeneca’s Vaxzevria; Philipp Rosenbaum, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Valneva’s promising initial Phase III data, with at least equal protection levels and […]
Read more

Arcutis may face challenges when marketing roflumilast despite commercial advantage, says GlobalData

Arcutis Biotherapeutics recently announced the submission of a New Drug Application (NDA) for its topical phosophodiesterase 4 (PDE4) inhibitor, roflumilast cream (ARQ-151), in the treatment of mild-to-severe plaque psoriasis (PsO). Despite having a potential commercial advantage as the first topical PDE4 inhibitor for an underserved PsO patient segment, GlobalData, a leading data and analytics company, […]
Read more
1 … 54 55 56 57 58 … 108